Last updated: 2026-09-05 12:46:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
PUMA BIOTECHNOLOGY INC. (PBYI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $9,56, with a market capitalization of $500,20M and a P/E ratio of 18,18. Over the past 52 weeks, its price has ranged from $4,30 to $9,74. This page covers its latest market performance, valuation, price trends and company information.
$500,20M | |
$9,44 | |
$279,37 | |
$1,60 | |
$9,41 | |
142,16K | |
-- | |
18,18 | |
$9,74 | |
$4,30 | |
-- | |
-- |
PUMA BIOTECHNOLOGY INC. (PBYI) last closed at $9,41 as of 2026-09-04 23:31:00, unchanged from the previous close of $9,41.
During the latest regular trading session, PBYI traded between $1,60 and $279,37, with a volume of 142,16K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, PUMA BIOTECHNOLOGY INC. (PBYI) moved from $9,02 to $9,56, representing a gain of 5,98% ($0,54).
The stock traded between $9,31 and $9,62 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 283,02 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 96,8%
PBYI is currently trading at $9,56, placing it 96,8% of the way from its 52-week low of $4,30 to its 52-week high of $9,74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 179 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PUMA BIOTECHNOLOGY INC. (PBYI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.